Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084791 | 0.78 | CYP2A6 (0.56) | CYP2A6 | |
| SCHEMBL9532005 | 0.74 | CA2 (0.56) | CA2 | |
| SCHEMBL2583566 | 0.69 | CYP2A6 (0.47) | CYP2A6 | |
| SCHEMBL15989403 | 0.67 | CYP2A6 (0.45) | CYP2A6 | |
| SCHEMBL22832614 | 0.67 | CYP2A6 (0.45) | CYP2A6 | |
| SCHEMBL9376598 | 0.67 | CA2 (0.52) | CA2 | |
| SCHEMBL13369132 | 0.67 | CA2 (0.41) | CA2 | |
| SCHEMBL9533435 | 0.65 | CA2 (1.00) | CA2CYP2A6 | |
| Hydrochloric Acid SCHEMBL9534585 | 0.63 | CA2 (1.00) | CA2CYP2A6 | |
| SCHEMBL9534654 | 0.63 | CA2 (0.45) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049200-B1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2015-04-29 | — | — | EP | disclosed |
| US-8440643-B2 | Inhibitors of beta-lactamase | METHYLGENE INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2049200-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MethylGene Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008073142-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-0375320-B1 | Substituted thieno(3,2-B) thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors | MERCK & CO INC (US) | 1993-11-24 | — | — | EP | disclosed |
| EP-0375320-A1 | Substituted thieno(3,2-B) thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors | MERCK & CO. INC. (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4876271-A | GLAUCOMA | MERCK & CO., INC. (US) | 1989-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279983-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, MGAM2, PGLS | CA2 440/4885CYP2A6 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.